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Pulmonary Mucormycosis in a patient with   
Acute Myeloid Leukemia
Jonathan Pan, MD, Margaret Kasner, MD, Sheel Patel, MD, Gretchen Diemer, MD
InTroduCTIon
Mucormycosis is a rare fungal infection that is common 
amongst uncontrolled diabetics and immunocom-
promised patients. The most common clinical 
presentation is rhino-orbital-cerebral infection, which 
typically affects diabetics with ketoacidosis.1 Less 
commonly, pulmonary mucormycosis can occur in 
patients with hematologic malignancy, solid organ 
transplant and patients taking steroids or deferoxamine.1 
The following report describes a 25-year-old male 
with Acute Myeloid Leukemia (AML) who developed a 
pulmonary mucormycosis infection.  With a mortality 
rate of about 87%, this case represents a favorable 
outcome for a rare and often lethal diagnosis. 
CaSE dESCrIPTIon
A 25-year-old male with no past medical history presented 
to the hospital after two weeks of fatigue, shortness of 
breath and epistaxis. Lab work revealed leukocytosis 
with 43% blasts, anemia and thrombocytopenia.  A bone 
marrow biopsy confirmed the diagnosis of AML. After 
admission, the patient developed persistent fevers and 
CT scan demonstrated ground-glass opacities in bilateral 
lung fields. Blood and sputum cultures, respiratory 
viral panel and acid fast studies were negative and the 
patient was started on antifungals and broad spectrum 
antibiotics. Bronchoscopy with bronchoalveolar 
lavage did not reveal an infectious source. The patient 
underwent induction chemotherapy with idarubicin and 
cytarabine, which was initially well tolerated. However, 
he soon developed neutropenic fever, hypoxia, and a 
non-productive cough. The treatment was broadened 
from vancomycin, zosyn and micafungin to meropenem 
and ambisome. Cultures remained negative during this 
time and subsequent imaging revealed right-middle and 
left-upper lobe consolidations with a central lucency. 
ouTCoME and Follow uP
A CT-guided biopsy of the pulmonary consolidation 
was performed. Pathology revealed granulomatous 
inflammation with necrosis and silver stain showed 
sparsely septate hyphae consistent with mucormycosis. 
High-dose ambisome was initiated and the patient 
began to demonstrate signs of clinical improvement. 
He was discharged on a six-week course of intravenous 
ambisome. Follow-up imaging showed improvement of 
the consolidations and the patient was switched to oral 
posaconazle for six additional weeks.
dISCuSSIon
Mucormycosis is a rare opportunistic fungal infection 
caused by fungi in the mucorales order, including 
mucor, rhizopus and absidia.3 These fungi are ubiquitous 
in nature, commonly found in soil and decaying matter 
and released via airborne spores. Histologically, hyphae 
are seen in broad, irregular branches with few septations, 
as opposed to aspergilli, which have acute branching 
angles and many septations. Comprising a unique 
category of angioinvasive molds, tissue infarction is a 
hallmark of the disease process.4  Risk factors include 
diabetes, hematologic malignancy, solid organ or stem 
cell transplant, immunocompromised state, iron overload 
and treatment with deferoxamine.5  While incidence is 
difficult to estimate due to mucormycosis not being a 
reportable disease, it is estimated that approximately 500 
cases occur in the US each year.6  As rhino-orbital-cerebral 
infection is the most common clinical manifestation in 
diabetics, pulmonary mucormycosis is more commonly 
seen with hematologic malignancy, transplant patients 
and steroid or deferoxamine use. It is caused by direct 
inhalation of spores into bronchioles and alveoli, which 
presents as a rapidly progressing pneumonia with or 
without hemoptysis.7  Clinical presentation is similar to 
that of other angioinvasive molds such as aspergillus or 
fusarium, and diagnosis is therefore obtained by culture 
and pathology. Imaging can show non-specific findings 
such as focal consolidation, nodules, masses, or pleural 
effusions. A halo sign on CT scan, which shows ground 
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glass attenuation surrounding a nodule, is characteristic 
of pulmonary aspergillus. A reverse halo-sign, on the 
other hand, shows focal ground glass attenuation within 
a ring of consolidation and is more commonly seen with 
mucormycosis. As cultures are typically negative, tissue 
diagnosis is often pursued.  A biopsy with silver stain will 
typically reveal broad, irregular, branching hyphae. 
In cases where pulmonary mucormycosis is localized to a 
single lobe, surgical excision can be performed. However, 
first line treatment for pulmonary mucormycosis remains 
high-dose, intravenous amphotericin B. Liposomal 
amphotericin is preferred due to improved efficacy and 
safety, although renal function and electrolytes must 
nonetheless be carefully monitored. Treatment should 
be initiated for several weeks until the patient clinically 
improves. At this time, amphotericin may be switched to 
oral posaconzale , which is often continued for several 
months until attainment of both clinical and radiographic 
resolution. 
KEy PoInTS
This case represents a rare and difficult diagnosis of 
pulmonary mucormycosis in a patient with hematologic 
malignancy. While a rapidly progressive disease with a 
high mortality rate, the patient in this case experienced a 
favorable outcome. Diagnosis was made only after invasive 
testing and successful treatment was achieved with an 
extended course of high dose intravenous ambisome.
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